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Background: The aims of this study were to evaluate the associations between the maximum standardized uptake
value (SUVmax) and prognostic factors in invasive lobular carcinoma (ILC) and to compare these results with those
in invasive ductal carcinoma (IDC).
Methods: The study included pathologically confirmed ILCs (n = 32) and IDCs (n = 73). We retrospectively evaluated the
preoperative 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) and
measured the SUVmax. The pathologic results were reviewed regarding the size, histological type, histological grade,
estrogen receptor (ER) and progesterone receptor (PR) status, human epidermal growth factor receptor 2 (HER2),
epidermal growth factor receptor (EGFR), and Ki-67 of the primary tumor. We also compared the associations between
the SUVmax and prognostic factors.
Results: The mean SUVmax of the ILCs was significantly lower compared with that of the IDCs (P = 0.032). The SUVmax
increased with tumor grade (P < 0.001) and was higher with ER negativity compared with ER positivity (P = 0.007) in IDC.
The SUVmax was higher with EGFR positivity compared with EGFR negativity (P = 0.013) in IDC and higher with Ki-67
positivity compared with Ki-67 negativity in IDC and ILC (P < 0.001 and P = 0.002, respectively). The SUVmax was not
significantly different regarding PR or HER2 for both tumor groups. The correlation between the tumor size and the
SUVmax was demonstrated for IDCs (r = 0.57), but not for ILCs (r = 0.25).
Conclusions: The SUVmax was significantly different according to the tumor grade, ER, EGFR, and Ki-67 for IDCs. The
SUVmax exhibited a positive association with Ki-67 in ILC; however, it was not significantly different with other factors,
which suggests that the role of 18F-FDG PET/CT may be limited in ILC.
Keywords: Breast neoplasm, Invasive lobular carcinoma, Invasive ductal carcinoma, Positron emission tomography/
computed tomography, Estrogen receptor, Progesterone receptorBackground
Breast cancer is a heterogeneous disease with a broad range
of therapeutic responses, recurrence risk, and overall prog-
nosis [1]. Predicting the prognosis of breast cancer is very
important to determine the direction of treatment. The
conventional prognostic factors include the tumor nuclear* Correspondence: rad-ksh@catholic.ac.kr
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The immunohistochemical prognostic factors include hor-
mone receptors, such as estrogen receptor (ER), progester-
one receptor (PR) and human epidermal growth factor
receptor 2 (HER2), and the Ki-67 proliferation index [2].
18F-fluorodeoxyglucose positron emission tomography/
computed tomography (18F-FDG PET/CT) has become
an increasingly important tool in the evaluation of pa-
tients with invasive breast cancer by revealing the func-
tional properties of breast tumors [1]. 18F-FDG uptake in
tumors is affected by various mechanisms, such as glucosehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tumor cells, tumor vascularity, tumor necrosis, the density
of tumor cells, and the mitotic activity index [3]. The max-
imum standardized uptake value (SUVmax) measured with
FDG PET is a sensitive indicator for metabolic activity in
breast cancer [4,5], which can be used to assess tumor ag-
gressiveness and is associated with prognostic factors, such
as the histological type, histological grade, immunohisto-
chemical factors, and proliferation index [2-4,6-10]. These
studies have primarily included invasive ductal carcinoma
(IDC), which comprises 72% to 80% of all invasive breast
cancers [11]. Invasive lobular carcinoma (ILC) is the second
most common breast cancer after IDC and accounts for
5% to 15% of all breast cancers [11,12], but there is a lack
of data associating the SUVmax and prognostic factors in
ILC in the existing literature. ILCs have exhibited low FDG
uptake in previous studies [3,4,7-9,13-15].
To our knowledge, no study has associated FDG uptake
with prognostic factors in this specific type of breast cancer.
Thus, the aims of this study were to associate the SUVmax
with histopathological and immunohistochemical prognos-




Institutional review board approval was obtained for this
retrospective study. The informed consent was waived. We
reviewed medical records and identified 32 patients with
ILC between January 2004 and June 2012 and 73 patients
with IDC in 2009. All patients underwent preoperative 18F-
FDG PET/CT, in addition to breast magnetic resonance
imaging and subsequent surgical diagnosis and staging.
18F-FDG PET/CT imaging
All patients underwent preoperative 18F-FDG PET/CT
examinations using a dedicated PET/CT scanner with
two-slice CT (Siemens Biograph Classic; Siemens Med-
ical Solutions, Knoxville, TN, USA) (n = 60) or with a
PET/CT scanner with 40-slice CT (Siemens Biograph
TruePoint; Siemens Medical Solutions, Knoxville, TN,
USA) (n = 45). The patients were asked to fast for a
minimum of 6 h prior to the examination. Serum glu-
cose levels were measured to ensure euglycemia (blood
glucose level <130 mg/dl). Approximately 370 to 550
MBq of 18F-FDG were then injected with saline infusion.
Following 60 min of bed rest after the injection, the PET
scans were obtained. Seven to eight bed positions were
acquired, with an acquisition time of 2 min each. All pa-
tients were in a supine position with their arms raised
during the PET/CT scanning. Noncontrast CT scanning
was initiated at the orbitomeatal line and progressed to
the upper thigh (30 mAs; 130 kV; slice thickness 5 mm);
the corresponding PET imaging immediately followedover the same body region. The CT data were used for
attenuation correction, and the images were recon-
structed using the standard ordered subset expectation
maximization (OSEM; two iterations, eight subsets)
algorithm.Imaging interpretation
The 18F-FDG PET/CT imaging data were interpreted retro-
spectively by a nuclear medicine physician. All PET/CT im-
ages were reviewed at a workstation with fusion software
(Syngo; Siemens Medical Solutions, Knoxville, TN, USA),
which provided multiplanar reformatted images and dis-
played PET images, CT images, and PET/CT fusion im-
ages. A nuclear medicine physician reviewed the PET/CT
images, and the interpretation was visually performed. For
semi-quantitative analysis, SUVmax of 18F-FDG was mea-
sured by visually placing the regions of interest (ROIs)
around the primary cancer mass that had perceptible 18F-
FDG uptake. For compensation of two different PET/CT
scanner types, the mean liver SUV values were obtained
for all patients. The tumor/liver SUV ratio was calcu-
lated and compared between two groups using the dif-
ferent PET/CT scanner types. The tumor/liver SUV
ratio was not statistically different according to the
PET/CT scanner types (2.11 ± 1.89 for biograph classic
with two-slice CT versus 1.75 ± 1.26 for biography true
point with 40-slice CT, P = 0.299).Histopathological analysis
We obtained the histopathological findings, including
the size of invasive cancer, histological type, histological
grade, ER and PR status, HER2, epidermal growth factor
receptor (EGFR), and Ki-67 of the primary tumor by
reviewing the pathology reports. Histopathological grad-
ing was performed using the Elson-Elis method, in
which tubule formation, pleomorphism, and mitotic
counts are scored 1 to 3 points. The cases scored within
the 3 to 5 range were designated as grade 1, within 6 to
7 as grade 2, and within 8 to 9 as grade 3. Immunohisto-
chemistry was used to assess the expression of the fol-
lowing molecular markers: ER, PR, HER2, EGFR, and
Ki-67. ER and PR positivity was defined as the presence
of 10% or more positively stained nuclei in ten high-
power fields. The intensity of HER2 immunohistochem-
ical (IHC) staining was scored as 0, 1+, 2+, or 3+. The
tumors with 3+ were classified as positive, whereas 0
and 1+ were negative. For an HER2 score of 2+, fluores-
cence in situ hybridization (FISH) was used to deter-
mine HER2 positivity. EGFR was considered positive if
membrane staining was observed. A Ki-67 of ≥15% was
considered positive expression, which is comparable to
2011 Galen Consensus [16] and previous other studies
of our institution [2,17].
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Continuous variables are shown as the mean ± standard de-
viation (SD) with or without median (interquartile range),
and the categorical variables are presented as the frequency
and percentage. The differences between patient age and
histopathological findings in ILCs and IDCs were com-
pared using the Wilcoxon rank sum and Kruskal-Wallis
tests. The association between the histopathological vari-
ables (for example, histological type, histological grade, ER
and PR status, HER2, EGFR, and Ki-67 of the primary
tumor) and the SUVmax were compared in each group of
total carcinomas, ILCs, and IDCs using the Wilcoxon rank
sum and Kruskal-Wallis tests. The correlations between
the tumor size and the SUVmax were determined by the
Spearman correlation coefficient and P value.
Significance was established at P < 0.05. The evaluation
of the results was performed using the SAS system for
Windows V 9.1 (SAS Institute, Cary, NC, USA).
Results
Patients and tumor characteristics
The clinical and histopathological data are summarized
in Table 1. The tumor size was significantly larger in theTable 1 Clinical and histopathological characteristics of ILC a
Total (n = 105)
Age (n = 105; 32, 73)a 52 ± 9.46
Tumor size (n = 104; 31, 73)a 2.25 ± 1.56
Tumor Grade (n = 105; 32, 73)a
Grade 1 35 (33.3)
Grade 2 53 (50.5)
Grade 3 17 (16.2)
ER (n = 104; 31, 73)a
Negative 20 (19.2)
Positive 84 (80.8)
PR (n = 103; 31, 72)a
Negative 33 (32.0)
Positive 70 (68.0)
HER2 (n = 91; 30, 61)a
Negative 74 (81.3)
Positive 17 (18.7)
EGRF (n = 98; 27, 71)a
Negative 82 (83.7)
Positive 16 (16.3)
Ki-67 (n = 99; 27, 72)a
Negative 57 (57.6)
Positive 42 (42.4)
Note: The age and tumor size were shown in mean ± standard deviation (SD) and o
in parenthesis.
a(n = number of total cases; number of ILC, number of IDC).
EGRF, epidermal growth factor receptor; ER, estrogen receptor; HER2, human epide
lobular carcinoma; PR, progesterone receptor.ILC group compared with the IDC group (2.64 ± 1.13 vs.
2.08 ± 1.69 cm; P = 0.002). Compared with IDCs, ILCs
were more likely to be positive for ER (93.6% vs. 75.3%;
P = 0.031) and PR (83.9% vs. 61.1%; P = 0.023) and less
likely to overexpress HER2 (6.7% vs. 24.6%; P = 0.039)
and Ki-67 (18.5% vs. 51.4%; P = 0.003).
The patient’s age, tumor grade, and EGFR of the pri-
mary tumor were not different between the ILCs and
IDCs.
SUVmax and histopathological variables
The association between the SUVmax and the histo-
pathological variables are summarized in Table 2. The
mean SUVmax of the ILCs (1.99 ± 1.72) was significantly
lower compared with the IDCs (3.91 ± 3.99) (P = 0.032).
The SUVmax increased with tumor grade (P < 0.001)
and was higher with ER negativity compared with ER
positivity (6.39 ± 5.06 vs. 3.09 ± 3.23; P = 0.007) in the
IDC group (Figure 1). The SUVmax was higher with
EGFR positivity compared with EGFR negativity (6.92 ±
5.55 vs. 3.26 ± 3.22; P = 0.013) in the IDC group (Figure 1)
and higher with Ki-67 positivity compared with Ki-67 nega-
tivity (5.58 ± 4.66 vs. 2.19 ± 2.15, IDC, P < 0.001; 4.18 ± 0.88nd IDC patients
ILC (n = 32) IDC (n = 73) P value
53.28 ± 9.52 51.44 ± 9.44 0.529
2.64 ± 1.13 2.08 ± 1.69 0.002
0.709
9 (28.1) 26 (35.6)
18 (56.3) 35 (48.0)
5 (15.6) 12 (16.4)
0.031
2 (6.5) 18 (24.7)
29 (93.6) 55 (75.3)
0.023
5 (16.1) 28 (38.9)
26 (83.9) 44 (61.1)
0.039
28 (93.3) 46 (75.4)
2 (6.7) 15 (24.6)
0.221
25 (92.6) 57 (80.3)
2 (7.4) 14 (19.7)
0.003
22 (81.5) 35 (48.6)
5 (18.5) 37 (51.4)
ther values were presented as number of cases and percentage
rmal growth factor receptor 2; IDC, invasive ductal carcinoma; ILC, invasive
Table 2 Association between clinical pathological variables and SUVmax values
SUVmax
Total (n = 105) ILC (n = 32) IDC (n = 73)
Mean ± SD Mean ± SD Mean ± SD
Median (interquartile range) Median (interquartile range) Median (interquartile range)
Cancer type (n = 105; 32, 73)a
ILC (n = 32) 1.99 ± 1.72
1.70 (0.50 to 3.05)
IDC (n = 73) 3.91 ± 3.99
2.30 (1.40 to 6.10)
P value 0.032
Tumor Grade (n = 105; 32, 73)a
Grade 1 (n = 35; 9, 26)a 2.07 ± 2.02 1.63 ± 1.36 2.22 ± 2.21
1.70 (1.10 to 2.40) 1.90 (0.00 to 2.40) 1.60 (1.20 to 2.30)
Grade 2 (n = 53; 18, 35)a 2.97 ± 3.37 1.76 ± 1.54 3.59 ± 3.88
2.20 (1.00 to 3.60) 1.60 (0.00 to 3.20) 2.30 (1.20 to 5.30)
Grade 3 (n = 17; 5, 12)a 7.02 ± 4.31 3.46 ± 2.46 8.51 ± 4.07
6.70 (4.50 to 8.40) 2.80 (1.50 to 5.30) 7.25 (6.05 to 11.90)
P value <0.001 0.393 < 0.001
ER (n = 104; 31, 73)a
Negative (n = 20; 2, 18)a 5.84 ± 5.10 0.80 ± 1.13 6.39 ± 5.06
5.55 (1.90 to 7.85) 0.80 (0.00 to 1.60) 5.95 (2.30 to 8.40)
Positive (n = 84; 29, 55)a 2.77 ± 2.83 2.14 ± 1.72 3.09 ± 3.23
1.95 (1.20 to 3.45) 1.80 (1.00 to 3.20) 2.10 (1.30 to 4.70)
P value 0.010 0.257 0.007
PR (n = 103; 31, 72)a
Negative (n = 33; 5, 28)a 4.82 ± 5.00 0.92 ± 0.85 5.52 ± 5.11
2.30 (1.30 to 7.30) 1.30 (0.00 to 1.60) 4.90 (1.55 to 7.55)
Positive (n = 70; 26, 44)a 2.71 ± 2.41 2.27 ± 1.76 2.97 ± 2.71
2.10 (1.30 to 3.50) 2.00 (1.00 to 3.40) 2.15 (1.40 to 4.10)
P value 0.157 0.089 0.064
HER2 (n = 91; 30, 61)a
Negative (n = 74; 28, 46)a 3.13 ± 3.51 2.03 ± 1.64 3.80 ± 4.14
2.10 (1.20 to 3.70) 1.75 (1.00 to 3.05) 2.15 (1.30 to 5.80)
Positive (n = 17; 2, 15)a 4.59 ± 4.16 2.65 ± 3.75 4.85 ± 4.26
3.50 (1.80 to 6.90) 2.65 (0.00 to 5.30) 3.50 (1.80 to 7.30)
P value 0.113 0.900 0.230
EGRF (n = 98; 27, 71)a
Negative (n = 82; 25, 57)a 2.85 ± 2.86 1.90 ± 1.44 3.26 ± 3.22
2.05 (1.20 to 3.50) 1.80 (1.00 to 2.90) 2.10 (1.30 to 4.80)
Positive (n =16; 2, 14)a 6.39 ± 5.45 2.65 ± 3.75 6.92 ± 5.55
5.55 (2.40 to 7.25) 2.65 (0.00 to 5.30) 5.95 (2.60 to 7.30)
P value 0.006 0.815 0.013
Ki-67 (n = 99; 27, 72)a
Negative (n = 57; 22, 35)a 1.90 ± 1.87 1.45 ± 1.22 2.19 ± 2.15
1.60 (1.00 to 2.30) 1.65 (0.00 to 2.30) 1.60 (1.10 to 2.30)
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Table 2 Association between clinical pathological variables and SUVmax values (Continued)
Positive (n = 42; 5, 37)a 5.41 ± 4.40 4.18 ± 0.88 5.58 ± 4.66
4.75 (2.30 to 7.30) 4.30 (3.40 to 4.70) 5.30 (2.20 to 7.30)
P value < 0.001 0.002 < 0.001
a(n = number of total cases; number of ILC, number of IDC).
EGRF, epidermal growth factor receptor; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; IDC, invasive ductal carcinoma; ILC, invasive
lobular carcinoma; PR, progesterone receptor.
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groups (Figures 1 and 2). The SUVmax was not signifi-
cantly different according to PR or HER2 for both tumor
groups.
A correlation between the tumor size and the SUVmax
was identified in IDCs (r = 0.57), but not ILCs (r = 0.25)
(Table 3).
Discussion
The objectives of this study were to associate the SUV-
max with prognostic factors in ILC and to compare
these results with the associations in IDC.
In the present study, the tumor size was significantly
larger in the ILC group compared with the IDC group.
Compared with IDCs, ILCs were more likely to be posi-
tive for ER and PR and less likely to overexpress HER2
and Ki-67. The results of the present study are consist-
ent with previous studies [12,18,19].
In the present study, because the distributions of
SUVmax values were skewed, the association between
clinical/histopathological variables and SUVmax values
was performed by the Wilcoxon rank sum test. OurFigure 1 A 57-year-old woman with invasive ductal carcinoma in the
upper outer breast with a maximum standardized uptake value (SUVmax) m
study, ER and PR were negative and Ki-67 and EGFR were positive. (b) 18F-F
lymph node with a SUVmax measured at 5.8. On histologic examination, ri
lymph nodes. EGFR, epidermal growth factor receptor; ER, estrogen recepto
tomography/computed tomography; PR, progesterone receptor.study revealed that the mean SUVmax of ILCs was sig-
nificantly lower compared with that of IDCs, which was
consistent with previous results [3,4,7-9,13-15]. The
lower FDG uptake of ILC was explained by diffuse infil-
trative growth patterns, a low tumor cell density, a low
level of GLUT1 expression, and a decreased prolifera-
tion rate [3,13,15]. The SUVmax was significantly differ-
ent according to the tumor grade, ER, EGFR, and Ki-67
for IDCs; however, only Ki-67 was significantly different
for ILCs in the present study. The SUVmax was not sig-
nificantly different according to PR or HER2 for both
tumor groups. These results for IDCs were consistent
with previous studies regarding breast cancers in which
the SUVmax was significantly higher in patients with
tumors with negative ER and grade III [2,4,6-10,14,20].
There have been some controversies regarding the associ-
ation between the SUVmax and the negativity of PR
[2,4,6,8-10,14,20] and the positivity of EGFR [2,9]. There
was no association between the SUVmax and HER2 status
in IDC or ILC in the present study, and these findings are
nearly identical to previous results [2,4,6,8-10,14,20]; how-
ever, the current findings are in disagreement with previousright breast. (a) 18F-FDG PET/CT shows focal FDG uptake in the right
easured at 13.6. The tumor grade was III. On immunohistochemical
DG PET/CT at axillary level shows focal FDG uptake in the right axillary
ght axillary lymph node metastases were noted in 7 of 16 dissected
r; 18F-FDG PET/CT, 18F-fluorodeoxyglucose positron emission
Figure 2 A 76-year-old woman with invasive lobular carcinoma
in the left breast. 18F-FDG PET/CT shows focal FDG uptake in the
left mid outer breast with a maximum standardized uptake value
(SUVmax) measured at 5.3. On immunohistochemical study, Ki-67
was positive. 18F-FDG PET/CT, 18F-fluorodeoxyglucose positron
emission tomography/computed tomography.
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SUV max and HER2 positivity [10,14].
In contrast with IDC, the SUVmax showed a positive as-
sociation only with Ki-67 in ILC in the present study. The
association between the SUVmax and the Ki-67 prolifera-
tion index in breast carcinoma has been reported in previ-
ous studies [2,4,6,7]; however, the majority (84% to 100%) of
cases in these studies had IDCs. To the best of our know-
ledge, no previous report has evaluated the association be-
tween the SUVmax and prognostic factors in ILC. The role
of 18F-FDG PET/CT as an imaging biomarker to predict the
prognosis in breast cancers has been demonstrated in many
papers [2-4,6-10,14]. We have also demonstrated the role of
18F-FDG PET/CTas an imaging biomarker for the prognos-
tic prediction of breast cancers in IDC. However, the role of
18F-FDG PET/CT may be assumed to be limited in ILC.
The correlation between the tumor size and the SUV-
max was demonstrated in IDCs, but not in ILCs in the
present study. The IDC results in the present study were
similar to previous studies that reported a positive rela-
tionship between SUVmax and tumor size in breast can-
cer [2,6,7,9,10,14], but not consistent with previous
result that indicated there was no correlation between
the SUVmax and T stage [8].Table 3 Correlation between Tumor size and SUVmax
Total ILC IDC
(n = 105) (n = 32) (n = 73)
Spearman correlation coefficient 0.40 0.25 0.57
P value <0.001 0.1787 <0.001
IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; SUVmax,
maximum standardized uptake value.The limitations of the current study included the small
number of cases, especially for ILC, and the retrospective
design. Furthermore, the reviewers were aware that all
cases had breast cancer, although they did not know
whether the diagnosis was IDC or ILC, which may have re-
sulted in selection bias. Because the review of histopatho-
logical report was also retrospective, the data file included a
certain amount of missing values. The high rate of missing
values for HER2 was due to lack of FISH results for cases
showing HER2 score of 2+ on IHC staining, because the
FISH was not a routine exam but an ancillary test based on
request by clinicians. The missing values had less than 15%,
so the list-wise deletion was used for missing data.
Conclusions
In conclusion, the mean SUVmax of ILCs was signifi-
cantly lower compared with that of IDCs. The SUVmax
was significantly different according to the tumor grade,
ER, EGFR, and Ki-67 in IDCs, but only for Ki-67 in
ILCs. Therefore, the role of preoperative 18F-FDG PET/
CT in terms of prognosis prediction may be more diffi-
cult in ILCs than IDCs.
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